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Objectives: Early detection of oral squamous cell carcinoma (OSCC) is critical, 
because of its rapid growth, aggressive infiltration, frequent lymph node metastasis and 
poor prognosis. However, clinically valuable tools and biomarkers from systemic study 
for early diagnosis of OSCC have not been established yet. The purpose of this study 
was to identify candidate biomarkers for OSCC for early diagnosis with genetic and 
bioinformatical verification. 
Materials and Methods: Tumor and normal tissues from patients with OSCC were 
used for microarray analysis. Differentially expressed genes, identified using 
permutation, local pooled error (LPE), and t-tests and significance analysis of 
microarrays (SAM) were investigated with ontological analysis and selected as 
candidate genetic markers. These genes were validated via quantitative reverse 
transcription polymerase chain reaction (qRT-PCR).  
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Results: Two groups corresponding with tissue identity were evident, implying that 
their differentially expressed genes represented the biological differences between 
tissues. Fifteen genes were identified using Student’s t-test (p<0.05) and SAM. Based 
on gene expression, these 15 genes were distinguished in OSCC samples. Genetic 
analysis of functional networks and ontologies, validated by qRT-PCR of tissue samples, 
identified four genes, ADAM15, CDC7, IL12RB2 and TNFRSF8, demonstrating 
favorable concordance with microarray data. 
Conclusion: ADAM15, CDC7, IL12RB2 and TNFRSF8 can be candidate biomarkers for 
the diagnosis of OSCC. 
Keywords : biomarker, oral squamous cell carcinoma, microarray, quantitative reverse 
transcription polymerase chain reaction, gene expression profiling. 
Student Number : 2006-30985 
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I. Introduction 
Oral squamous cell carcinoma (OSCC) is the sixth most common malignancy 
worldwide, accounting for 3% of all cancers (1,2), and it remains one of the most 
intractable malignancies due to its invasive growth pattern, frequent cervical lymph-node 
metastasis and high recurrence rate (3). Approximately two-thirds of patients with OSCC 
exhibit an advanced stage (Stage III or IV) at diagnosis because lesions are often 
asymptomatic and clinicians cannot predict the biological relevance of lesions on the 
basis of their physical features alone (4,5). As OSCC is associated with severe 
morbidities and a low 5-year survival rate (approximately 50%), especially for advanced-
stage disease (41% for Stage III and 9% for Stage IV), early detection is critical (6,7). For 
that purpose, screening methods, such as light-based screening or brush cytology, have 
been introduced, but their sensitivity and specificity are insufficient compared with those 
of scalpel biopsy. Hence, histopathological examination is still a cornerstone of diagnosis; 
however, excluding the possibility of misdiagnosis completely is difficult due to the 
inherent vagueness of the histopathological characteristics of OSCC and variations in the 
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pathologists’ experience. 
Recently, mRNA biomarkers for OSCC in serum or tissue have become new diagnostic 
and therapeutic targets because suitable biomarkers can improve the power, availability 
and cost-effectiveness of high-throughput screening for genetic alterations. Microarray 
analysis, validated with the quantitative reverse transcriptase polymerase chain reaction 
(qRT-PCR), has been used to identify the genes underlying OSCC pathogenesis, which 
include IL-8, vascular endothelial growth factor (VEGF) (8), laminin γ2 (LAMC2) / 
collagen type IV α1 (COL4A1) and collagen type I α1 (COL1A1) / peptidyl arginine 
deiminase, type I (PADI1) (9), and the homeobox (HOX)-genes model HOXA5 / 
HOXD10/ HOXD11 (10). Some investigators have employed a multiple-gene model of 25 
biomarkers with 86%-89% accuracy (11). However, no studies have established 
clinically-valuable biomarkers, which may be due to a lack of studies with tumor-normal 
(TN) paired matching of patients (10) or to the limited predictive power of microarray-
based models to correlate the clinical endpoint with gene expression (12). This study is 
aimed to identify the candidate biomarkers of OSCC using TN- paired matching samples, 
verified by bioinformatical methods with reduced statistical error. 
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II. Materials & Methods 
Patients 
Tumor and normal tissues from five OSCC patients were used for the microarray 
analysis. Subsequently, tissues from 17 OSCC patients (TN-paired) were used for the 
qRT-PCR analysis. Fresh tissue samples were collected after obtaining written informed 
consent from 33 consecutive patients undergoing therapeutic surgical resection for OSCC 
between 1 June 2011 and 28 June 2012. The patients’ characteristics are outlined in table 
1.  
After excision, tissues were preserved immediately in RNAlater® solution (Invitrogen, 
Waltham, MA, USA) and were transferred to the laboratory on ice. This trial was 
approved by the Institutional Review Board at Seoul National University Dental Hospital 
and was conducted in full accordance with the Declaration of Helsinki. 
RNA extraction and cDNA synthesis  
RNAlater® was pipetted off the pellet, and the pellet was then washed with ice-cold 
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phosphate-buffered saline, which was removed after centrifugation. Total RNA was 
extracted from the tissue samples with the RNeasy® Mini Kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s instructions. To quantify and analyze the integrity of 
RNA, 2100 Bioanalyzer® (Agilent Technologies, Santa Clara, CA, USA) was used. 10 μg 
of total RNA was reversely transcribed in the presence of an oligo (dT) T7 primer 
(iScript™ Select cDNA Synthesis Kit; Bio-Rad Laboratories, Hercules, CA, USA). 
cDNA was used for in-vitro transcription amplification in the presence of biotinylated 
nucleotides.  
Microarray analysis 
Gene expression was analyzed using the Affymetrix preparation protocol before 
hybridization to a Gene-Chip® 1.1 human genome microarray (Affymetrix, Santa Clara, 
CA, USA). Quality control of the arrays was achieved through analysis of the 5’:3’ ratios 
(range: 0.40-0.79), the percentage present (range: 37-47%), the average pair-wise 
correlation, and the principal component. Affymetrix ® Microarray Suite version 5.0 
(Affymetrix, Santa Clara, CA, USA) was used for image processing and data acquisition. 
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Gene expression levels and individual exon signal estimates contained in *. CEL files 
within the GeneChip® 1.1 platform (Affymetrix, Santa Clara, CA, USA) were derived by 
the robust multi-array average (RMA) algorithm, as implemented by the Expression 
Console v1.1.1 (Affymetrix, Santa Clara, CA, USA). The quality of the data was assessed 
by analyses of the mean overall expression and its standard deviation, the detectable 
probe ratios, the control probe’s (housekeeping genes) expression data, and the 
correlation between samples from the same tissue. 
qRT-PCR 
Target and housekeeping gene sequences were retrieved from the GenBank® database 
(National Center for Biotechnology Information (NCBI), Bethesda, MD, USA), and 
applied primers were manually designed using the Primer-BLAST® tool (NCBI, Bethesda, 
MD, USA). Primer sequences are listed in Table 2. RNA mixtures were subjected to first-
strand cDNA synthesis using forward primers. The endogenous housekeeping genes, 
hypoxanthine guanine phosphoribosyl transferase (HPRT) and β–actin (ACTB), were used 
for data normalization, and relative quantification was performed with a relative standard 
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curve analysis with a CFX Connect™ Real-Time PCR Detection System (Bio-Rad 
Laboratories, Hercules, CA, USA) and SYBR® Green I (Bio-Rad Laboratories, Hercules, 
CA, USA) detection. cDNA (10ng) was dissolved in iQ™SYBR® Green Supermix (Bio-
Rad Laboratories, Hercules, CA, USA). The PCR comprised an initialization cycle (95°C 
for 3 minutes); 39 cycles of 95°C for 10 seconds, 56°C for 10 seconds, 72°C for 20 
seconds, and plate reading at 80°C; and a final melting step at temperatures ranging from 
56 to 95°C at a heating rate of 0.5°C/10 seconds, which was performed to create melt 
curves. The qRT-PCR was performed in quadruplicate for each cDNA samples, and 
negative controls with no template were included for each primer pair. Threshold cycle 
(Ct) values and target gene expression levels were calculated using CFX Manager™ 
Software ((Bio-Rad Laboratories, Hercules, CA, USA). The fold change of target gene 
expression in each treated sample, relative to the control sample, was derived from the 
negative Ct value: Ct (GAPDH)−Ct (target gene). 
Data analysis and prediction models 
Differences in the clinical characteristics between the Microarray Study and the qRT-
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PCR Validation groups were compared using the Chi-square test. If this method was not 
suitable, a Fisher’s exact test or a linear-by-linear association test was used. Differentially 
expressed genes (DEGs), identified with four statistical tests (permutation test, local 
pooled error (LPE) (13), Student’s t-test, and significance analysis of microarrays (SAM) 
(14), were selected as candidates for genetic biomarkers (15), and their normalities were 
tested using the Shapiro-Wilk test (16). After the normality had been tested, genes that 
were normally distributed were assessed using the Student’s t-test, the SAM and the LPE 
(parametric methods). The genes that were not distributed normally were assessed using a 
non-parametric permutation test. For the multiple-comparison problem, p-values were 
adjusted using the false discovery rate (FDR) correction. To find candidates, FDR values 
as close to 0% as possible were used , and those for the SAM and the permutation test 
were set to 0%. On the other hand, the FDRs for the LPE and the Student’s t-test were set 
to 0.001% and 0.02%, respectively, because no significant candidate genes were found 
when their FDRs were set to 0%. A discriminant analysis was used to find correlations 
between the candidate gene expressions and clinical parameters such as tissue 
heterogeneity, site specificity, and stage differences. From receiver-operating 
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characteristic (ROC) curves, the area under the curve (AUC), the sensitivity, the 
specificity, and the predictive value of each candidate gene were calculated using the 
Youden index. All statistical analyses, except the analyses of the ROC curves, which 
were done using Med-Calc® Statistical Software version 12.7.8 (MedCalc® Software bvba, 
Oostende, Belgium), were conducted using R Statistical Software version 2.15.0 (from 
http://www.r-project.org/) and IBM SPSS® version 20 (IBM Co., Armonk, NY, USA). 
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IV. Results 
Patient characteristics  
Thirty-three patients with OSCC, 17 men (51.5%) and 16 women (48.5%), were 
included in this study (Table 1). The DEGs in five patients were analyzed  with 
microarray analysis to compare primary TN-paired tissue samples. Tumor (n=20) and 
normal tissues (n=25) from another 28 patients were used for the qRT-PCR validation. Of 
those 28 patients, 17 were assayed for expression via the qRT-PCR of primary tumor 
samples and matched normal mucosa. No statistically significant differences in clinical 
characteristics between the microarray study and the qRT-PCR validation groups were 
observed (p > 0.05). 
Statistical analysis of candidate genes identified with a microarray analysis  
All data were found to be followed a normal distribution in Shapiro-Wilk test. 
Therefore, parametric methods (the Student’s t-test, the SAM and the LPE) were used to 
identify DEGs. The LPE test was proposed to overcome the limitation caused by the 
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different error variances arising from the diverse biological conditions via local error 
estimation within quantiles and non-parametric smoothing (13). The SAM scores gene 
expression relative to the deviation of repeated measurements in order to identify genes 
with high scores above an adjustable threshold, and for those identified genes, the FDRs 
and the percentage of identification by chance were estimated (Figure 1) (14). Of the 
33,297 genes on the microarray, the numbers of genes with significance, which were 
assessed with the Student’s t-test, the SAM and the LPE (parametric methods), were 
779, 349 and 200, respectively. None of these genes showed statistical significance in 
all 3 methods, but fifteen genes passed the Student’s t-test (p <0.05) and the SAM 
analysis. To test the ability of this signature gene set to classify the OSCC and the 
Normal groups, an average linkage hierarchical clustering analysis was performed. 
Based on gene expression, this 15-gene set had classification power for OSCC (Figure 
2).  
In this set, upregulated genes were family with sequence similarity 213, member B 
(C1orf93, FAM213B), Rho guanine nucleotide exchange factor 16 (ARHGEF16), zinc 
finger and BTB domain containing 48 (ZBTB48), DNA cross-link repair 1B 
(DCLRE1B), late cornified envelope 1D (LCE1D), kelch domain containing 7A 
(KLHDC7A), Tumor necrosis factor receptor superfamily, member 8 (TNFRSF8), 
Interleukin 12 receptor, beta 1 (IL12RB2), Cell division cycle 7 (CDC7) and A 
disintegrin and metallaproteinase metallopeptidase domain 15 (ADAM15), while 
UTP11-like, U3 small nucleolar ribonucleoprotein (UTP11L), polo-like kinase 3 
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(PLK3), WD repeat domain 63 (WDR63), potassium voltage-gated channel, Shaw-
related subfamily, member 4 (KCNC4) and ATPase, aminophospholipid transporter, 
class I, type 8B, member 2 (ATP8B2) were downregulated (Table 3).
Analysis of the literature related to candidate genes 
An ontological analysis revealed the function and the disease association of each gene, 
identifying genes involved in inflammation or immunity (FAM123B, ZBTB48, TNFRSF8 
and IL12RB2), intercellular signaling and movement (ARGHEF16, KCNC4 and 
ADAM15), transcription (UTP11L and ATP8B2), cell division (PLK3, CDC7 and 
DCLRE1B) and keratinization (LCE1D) (17-27). After a literature review, well-known 
genes associated with carcinogenesis, such as PLK 3 and KCNC 4, and unidentified genes, 
including WDR63 and KLHDC7A were excluded. Among the remaining genes, 
upregulated ones were chosen as candidates. Of them, ARHGEF16 and DCLRE1B were 
excluded due to their unknown correlation with oral cancer. Finally, IL12RB2, TNFRSF8, 
ADAM15 and CDC7 remained. According to previous research, these 4 genes are known 
to be related to inflammation, carcinogenesis or metastasis (17,19,21,22). 
- 12 - 
qRT-PCR validation of gene expression 
Expressions of the four candidate genes, ADAM15, CDC7, IL12RB2 and TNFRSF8, 
were assayed with the qRT-PCR in 28 OSCC samples to correlate microarray data with 
the qRT-PCR data and to explore potential biomarker expression (Figure 3). Relative 
expression levels of the four genes were obtained by normalization to housekeeping gene 
expression levels. The qRT-PCR expression values for the four candidate genes, whose 
expression levels were higher in tumor tissues compared with normal tissues, were used 
for correlation analyses using the 2-ΔΔCt method with the Student’s t-test. In the tumor 
group, statistically-significant high mRNA expression levels of ADAM15 and CDC7 were 
consistently detected with the qRT-PCR (p<0.001 and p<0.001, respectively), thus 
showing a good correlation with the microarray data. A higher expression in the tumor 
relative to normal tissue was particularly evident for CDC7 in its increased 2-ΔΔCt value.  
The mRNA expression of the selected genes in 17 TN-paired tissue samples was also 
measured with the qRT-PCR. The normalized expression was calculated with the 2-ΔΔCt 
method, as previously described, to compare normal and tumor tissues. ADAM15
expression was significantly increased in tumor tissues (p<0.001) by an average of 2.7-
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fold compared with normal tissues (Figure 4). Consistent with these findings, 
upregulation of CDC7 was evident in tumor tissues (p < 0.05). Furthermore, the candidate 
genes were overexpressed regardless of variability in the degree of expression between 
samples in the TN-paired group.  
Evaluation of the diagnostic validity of candidate genes 
The relationships between the clinical parameters and the candidate genes are 
summarized in Table 4. Classification of the primary sites with all four candidate genes as 
signatures resulted in moderate accuracy (64.7%) than using the ADAM15 (35.3%), 
CDC7 (47.1%), IL12RB2 (23.5%), and TNFRSF8 (41.2%) by themselves. Similar 
tendency was also observed regarding tissue heterogeneity and staging. These results 
imply that a combination of multiple candidate genes has a discriminatory power that is 
superior to that achieved with each candidate gene alone. ROC plots are presented in 
Figure 5, and their diagnostic indices were shown in Table 5. The AUCs of ADAM15, 
CDC7, IL12RB2 and TNFRSF8 were 0.699, 0.645, 0.561 and 0.602, respectively. 
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ADAM15 alone, however, showed significance (p < 0.05). Similarly, the odds ratio of 
ADAM15 (7.271; p = 0.029) and CDC7 (26.794; p = 0.046) were significant. 
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V. Discussion 
The five-year survival rate of patients with OSCC has remained about 50% for several 
decades. This is one of the worst prognoses of all cancers and is directly related to the 
advanced stage at diagnosis (28). For the early diagnosis of OSCC, biomarkers should be 
minimally invasive as possible with simple procedure and rapid result. Biomarkers of 
OSCC can be DNA, mRNA, proteins, metabolites, or process such as apoptosis, 
angiogenesis or proliferation in tissue, saliva and serum. Biomarkers from body fluid are 
non invasive and easy to access, but their accuracy and sensitivity are not reliable and 
preicise localization of lesion is difficult. As OSCC is multi-factorial with heterogenic 
pathogenesis, combination of mRNA or protein biomarkers with different sources is 
necessary for the discrimination between tumor and controls (29,30). Thus identification 
of candidate mRNA biomarkers is the fundamental for the establishment of systemic 
OSCC biomarkers. Moreover, local recurrence and distant metastasis may develop 
despite an apparently complete excision and histopathologically tumor-free margins, 
supporting the theory of field cancerization, defined as malignant or premalignant 
changes in an entire field of apparently normal tissue surrounding a tumor in response to 
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carcinogens (31). mRNA biomarkers could allow a more sensitive and accurate surgical 
margin to be determined. However, genome research has been hindered by individual and 
ethnic differences (32). Identification of OSCC-specific biomarkers in the populations is 
therefore necessary.  
Although the sample size of the microarray study group (n = 5) seems too small, 
accurate result can be ensured in in three ways: (i) several statistical analyses (the 
permutation test, Student’s t-test, the LPE and the SAM), which can identify significant 
DEGs with a small number of microarrays, were applied (13), (ii) genes carefully selected 
with these statistical tools were validated via the qRT-PCR with sufficient samples, and 
(iii) as shown in Table 1, patients’ clinicopathological characteristics were evenly 
distributed in both the microarray study and the qRT-PCR Validation groups. In spite of a 
general consensus that smoking history is a major contributor to carcinogenesis (33), gene 
expression between smoking and non-smoking subjects did not differ in this study.  
Further, Méndez et al. observed no significant differences in gene expression between 
patients with different histopathologic stages when using oligonucleotide arrays (34). 
Thus, the effect of smoking history and histopathological type on the results can be 
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expected to be minimal.  
To date, many studies have attempted to identify candidate biomarkers for OSCC (3,8-
10). However, they were not generally accepted for the following reasons: First, 
candidate biomarkers yielded by the microarray analysis were usually identified based on 
fold changes (9), but these can often be misleading, as different error variances exist 
under different biological conditions and in different microarray expression intensity 
ranges (13). Second, most previous studies mainly focused on well-known genes, such as 
matrix metalloproteinases (MMPs), p53 and VEGF (8). Such an approach could result in 
a bias against unknown genes, so selection of candidates with a microarray anlysis which 
is a relatively unbiased high-throughput method and reducing the statistical error with 
four kinds of biostatistics verification can overcome such prejudices.  
From these results, 15 genes were initially screened (Table 3). After exclusion of 
genes with unknown functions as previously mentioned, eight genes (ARHGEF16, 
DCLRE1B, TNFRSF8, PLK3, IL12RB2, CDC7, KCNC4 and ADAM15) are reportedly 
associated with cancer. Particularly, PLK3 and KCNC4 are well-known DEGs in head 
and neck cancer. PLK3 is an important mediator of the cellular responses to genotoxic 
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stresses and known to regulate the activity of p53 (35). PLK3 down-regulation in OSCC 
tissue is consistent with results of studies of both head and neck and esophageal SCC 
(23,36), suggesting that PLK3 downregulation functions in SCC tumorigenesis. KCNC4, 
encoding components of voltage-gated potassium channels, is reportedly overexpressed 
in head and neck cancer (32) ; however, it was downregulated in OSCC tissue in this 
study. Tumor markers secreted by tumor cells or released subsequently to tumor-cell 
fragmentation are valuable, because they are quantitatively more highly expressed than 
downregulated genes, and thereby increase the sensitivity of cancer diagnosis (37), thus
PLK3 and KCNC4 were excluded. As illustrated in Figure 2, upregulated genes whose 
functions are related to cancer comprise ARHGEF16, DCLRE1B, TNFRSF8, IL12RB2, 
CDC7 and ADAM15. However, few studies report an association between ARHGEF16
and DCLRE1B in head and neck malignancies. Therefore, the remaining four genes 
(ADAM15, CDC7, IL12RB2 and TNFRSF8) were selected for further evaluation using 
qRT-PCR. 
ADAM15 is the only member of a disintegrin and metalloproteinase (ADAM) family 
with an RGD (Arg-Gly-Asp) binding motif, enabling it to bind to integrins (38) and is 
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involved in T-cell-mediated immune responses and pathologic neovascularization,
implicated in several processes associated with tumor progression and inflammation (39). 
It is upregulated in breast, stomach, lung, pancreas, and prostate cancer and in metastatic 
progression (40). Conversely, its tumor suppression in melanomas and colon carcinomas 
was also proposed (38,41). This inconsistency might result from the complexity of the 
ADAM15-related signal transduction pathways. In this study, ADAM15 was significantly 
upregulated in patients with OSCC. CDC7, a serine threonine kinase, is a core component 
of the initiation machinery of DNA replication. Its activity is essential for S phase 
progression and inhibition of CDC7 in cancer cells induces p53-independent apoptosis 
(42). Clinically, increased CDC7 expression was found to be linked to tumor anaplasia, 
aneuploidy, advanced clinical stage and lower relapse-free survival, implicating CDC7
dysregulation in the development of aggressive disease in ovarian cancer, breast cancer, 
large B-cell lymphoma and malignant melanoma (42-45). Studies of human papilloma 
virus-related head and neck SCC demonstrated high expression of CDC7, similarly to 
other cell cycle regulators, such as cyclin-dependent kinase inhibitor 2A and cyclin-
dependent kinase inhibitor 2C (45). These results agreed with the data, which showed 
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overexpression of CDC7 in patients with OSCC. IL12RB2 encodes a type-1 
transmembrane protein, a subunit of the Interleukin 12 (IL-12) receptor complex: the 
cytokine IL-12 bridges innate and adaptive immunity and regulates T-cell, natural killer 
cell and B-cell function. IL12RB2 behaves as a tumor suppressor in human chronic B-cell 
malignancies, and its silencing is an early event in B-cell malignant transformation 
(32,46). Prolonged disease-free survival has also been reported to have been found in 
colorectal cancer patients with higher expressions of IL12RB2 (47). However, the 
correlation between IL12RB2 expression and OSCC development is unclear, a case of 
oesophageal squamous cell carcinoma in young adult with IL12RB1 deficiency was 
reported (48). Moreover, considering that interleukin 6 (IL-6) and IL-12 functionally 
antagonize each other and that IL-6-induced inflammation promotes carcinogenesis in the 
oral cavity (49,50), IL12RB2 downregulation might be involved in OSCC. However, 
despite overexpression of IL12RB2 in patients with OSCC in the microarray analysis 
group, no significant differences of IL12RB2 expression were found in this qRT-PCR 
data. TNFRSF8 is known to function in apoptosis by activating the caspase pathway (51) 
and protecting the body against autoimmunity. TNFRSF8 expression is upregulated in 
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various hematological malignancies, including Reed–Sternberg cells in Hodgkin's disease, 
anaplastic large-cell lymphoma and subsets of non-Hodgkin's lymphoma (52). It is a 
conventional biomarker of hematologic malignancies such as anaplastic large-cell 
lymphoma (53), but its relationship with solid tumors is unclear. Only one study reported 
that its overexpression might be associated with improved prognosis for patients with a 
skull base chordoma (54). Though TNFRSF8 in patients with OSCC was upregulated in 
the microarray analysis, qRT-PCR validation showed no significant differences.  
Among the four candidates, IL12RB2 and TNFRSF8 are known to be related to 
inflammation. Given that the oral cavity is vulnerable to frequent inflammatory stress 
and that this environment can affect cancer cells, these results support that inflammation 
might be correlated with OSCC development, as reported in some recent studies (8,50). 
Furthermore, the correlationship between OSCC and oral lichen planus (OLP) and graft-
versus-host disease (GVHD) can be deduced. OLP is a chronic inflammatory disease as 
a result of the T-cell-mediated autoimmune response and known as a premalignant 
lesion of OSCC (55). IL12RB2 and TNFRSF8 expression in OLP tissues were compared 
with non-OLP (mucositis) samples and TNFRSF8 was upregulated in OLP tissues as 
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similar to OSCC samples in the microarray results (56). These two genes are also 
related to GVHD, which has similar clinical and histopathological features to OLP (57). 
Chronic GVHD (cGVHD) has long been suspected to be a potential risk factor for 
secondary malignancies and several authors have detected OSCC in patients with 
extensive cGVHD (58). Taken together, OLP and GVHD seem to be associated with 
OSCC and these findings may contribute to identify therapeutic targets for OSCC, but 
further researches should be warranted.  
The correlation between the candidate genes and the clinical parameters (primary site, 
tissue heterogeneity and stage) were presented in Table 4. Although all p values were 
higher than 0.05, the eigenvalues and the accuracies of the signatures of the four genes for 
each parameter were generally lower than those of individual genes according to the 
Wilk’s lambda distribution analysis. This result indicates that the classifying power of the 
four genes combined was superior to that of each gene alone.  
As presented in table 5, the sensitivity, specificity and predictive values were calculated 
at the cut-off points according to the Youden index. At the cut-off points, the value of 
[sensitivity + specificity - 1] is a maximum (59). The Youden index is widely used to 
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determine the diagnostic threshold, and it is regarded as the most appropriate method of 
combining biomarkers (60). In terms of the AUC, ADAM15 showed higher clinical 
efficacy (p < 0.05) compared to the other candidate genes. The odds ratios of ADAM15 
and CDC7 also showed significant correlations to OSCC (p < 0.05).  
For further evalutions, the genetic product of candidates would be investigated with 
immunohistochemistry or western blot methods. Next generation sequencing could be a 
new method for the validation of candidate genes in genomic level also. But the 
dimension of the samples in this study were around 1cm  1cm, so it was difficult for 
further verification process after qRT-PCR analysis in same tissues. Large samples from 
different status and parameters, especially of the cancers developed from premalignant 
disease could contribute a variety of bioinformations for delicate diagnostic biomarkers, 
but serial sample collections of precancerous lesion from same patient are not easy to be 
obtained. Thus continuous investigation with diverse samples should be required to 
validate the clinical feasibility of candidates for the early diagnosis (61).  
 To conclude, ADAM15, CDC7, IL12RB2 and TNFRSF8 might be valuable candidate 
biomarkers for the early diagnosis of OSCC and further study should be necessary for the 
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establishment of systemic biomarkers for diagnosis and treatment of OSCC.  
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Table 
Table 1. Clinicopathologic characteristics of patients and the qualitative reverse 













Age (yrs)     
 <50 0 (0) 2 (10) 4 (16) 2 (11.8) 
50 5 (100) 18 (90) 21 (84) 15 (88.2) 
Gender     
 Male 4 (80) 10 (50) 12 (48) 9 (52.9) 
 Female 1 (20) 10 (50) 13 (52) 8 (47.1) 
Therapy prior to surgery     
 None 3 (60) 17 (85) 21 (84) 14 (82.4) 
 Yes 2 (40) 3 (15) 4 (16) 3 (17.6) 
Smoking history *     
 Yes 3 (60) 2 (10) 4 (16) 2 (11.8) 
 No 2 (40) 18 (90) 21 (84) 15 (88.2) 
Alcohol history     
 Yes 2 (40) 1 (5) 3 (12) 1 (5.9) 
 No 3 (60) 19 (95) 22 (88) 16 (94.1) 
Histological grading     
 Well-differentiated 2 (40) 12 (60) 16 (64) 11 (64.7) 
 Mod-differentiated 1 (20) 7 (35) 9 (36) 6 (35.3) 
 Poorly-differentiated 0 (0) 0 (0) 0 (0) 0 (0) 
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 Unknown 2 (40) 1 (5) 0 (0) 0 (0) 
Clinical stage     
 I/II 1 (20) 4 (20) 6 (24) 3 (17.6) 
 III/IV 4 (80) 16 (80) 19 (76) 14 (82.4) 
Lymph node involvement 
(Pathologic) 
 Negative 2 (40) 9 (45) 11 (44) 7 (41.2) 
 Positive 2 (40) 7 (35) 10 (40) 7 (41.2) 
 Unknown 1 (20) 4 (20) 4 (16) 3 (17.6) 
T classification (Pathologic)
 T1/T2 4 (80) 10 (50) 12 (48) 9 (52.9) 
 T3/T4a 1 (20) 10 (50) 13 (52) 8 (47.1) 
Tumor site     
 Alveolar gum 2 (40) 7 (35) 13 (52) 6 (35.3) 
 Tongue 2 (40) 4 (20) 3 (12) 3 (17.6) 
 Palate 0 (0) 4 (20) 3 (12) 3 (17.6) 
 Other 1 (20) 5 (25) 6 (24) 5 (29.4) 
Recurrence     
 Locoregional 
recurrence 
0 (0) 2 (10) 3 (12) 2 (11.8) 
 Lymph node 
metastasis 
2 (40) 2 (10) 2 (8) 2 (11.8) 
 Distal metastasis 0 (0) 2 (10) 2 (8) 2 (11.8) 
 No recurrence 3 (60) 14 (70) 18 (72) 11 (64.7) 
TN paired, tumor-normal matching among participants 
The Chi-squared or Fisher’s exact testswere used to compare the Microarray Study and 
Quantitative Reverse Transcription Polymerase Chain Reaction Validation Groups. 
* p < 0.05
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Table 2. Primer pairs for reverse transcription polymerase chain reaction validation of 
candidate biomarker gene expression levels. 
Gene Symbol RefSeq_ID Sequences (5’->3’) 
Target genes 
ADAM15 NR_040773.1 
Forward  CAG GAG ACA GCT CCC AGT GT 
Reverse  CAA AAG CAT TTC CCC GAG TA 
CDC7 NM_003503.3
Forward  GCT CAG CAG GAA AGG TGT TC 




Forward  ACT GGA GCC TCA GCA CAT CT 
Reverse  AGC CTC ACC ACT CAG AGC AT 
TNFRSF8 NM_001243.3
Forward  GCT CAG ATG TTT TGG GGA AA 




Forward  AGA GCT ACG AGC TGC CTG AC 
Reverse  GGA TGC CAC AGG ACT CCA 
HPRT NM_000194.2
Forward  ATC CAT TGG AGG GCA AGT C 
Reverse  GAG CTT TTT AAC TGC AGC AAC TT 
HPRT, hypoxanthine phosphoribosyltransferase 
ADAM15, a disintegrin and metalloproteinase metallopeptidase domain 15 
CDC7, cell division cycle 7 homolog 
IL12RB2, interleukin 12 receptor, beta 2 
TNFRSF8, tumor necrosis factor receptor superfamily, member 8 
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Table 3. Fifteen candidate genes whose expression differed between normal and tumor 
tissue in oral squamous cell carcinoma as indicated by microarray analysis (tumor–
normal-paired; n = 5). 
Gene 
Symbol







family with sequence 
similarity 
 213, member B 
(NM 001195736.1) 
Catalyzes the reduction of 




Rho guanine nucleotide 
exchange factor 16 
(NM 014448.3) 
Role in chemotactic cell migration and  
mediate activation of CDC42 by HPV16 
Unknown(Oliver et al, 
2011) 
ZBTB48 
zinc finger and BTB 
domain containing 
48(NM 005341.2) 
Binds to and regulates the J and/or S 
elements in MHC II promoter 
Unknown 
TNFRSF8 
tumor necrosis factor 
receptor superfamily, 
member 8 (NM 
001243.3) 
Positive regulator of apoptosis. Limit the 
proliferative potential of autoreactive 
CD8 
effector T cells and protect the body 
against the autoimmunity. 
Hodgkin disease, 
anaplstic large 
cell lymphoma  
(Durkop et al, 1992) 
UTP11L 




Involved in nucleolar processing of pre-
18S ribosomal RNA 
Unknown 
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PLK3 
polo-like kinase 3 
(NM 004073.2) 
Play a role in regulation of cell cycle 
progression and tumorigenesis 
Cancer, tumor  
(Li et al, 1996) 
IL12RB2 
interleukin 12 receptor, 
beta 2 
(NM 001258214.1) 
Role in the differentiation of T helper 1 
cell 
and promote the proliferation of T cells 
as well as natural killer cells. 
Allergic asthma, Burkitt 
lymphoma, 
autoimmunity (Bassuny
et al, 2003) 
WDR63 




cell division cycle 7 
homolog 
(NM 001134419.1) 
Phosphorylate critical substrates that 
regulate the G1/S phase transition 
and/or DNA replication 
Tumor, cancer, ataxia 
telangiectasia  





subfamily, member  
(NM 001039574.2) 
Mediates the voltage-dependent 
potassium ion permeability of excitable 
membranes 
Cancer, head  
and neck tumor 
(Menendez et al, 2010)
DCLRE1B 
DNA cross-link repair 
1B 
(NM 022836.3) 
Role in telomere maintenance and 
protection during S-phase 
Hoyeraal-Hreidarsson 
syndrome 
(Lenain et al, 2006) 
LCE1D 
Late cornified envelope 
protein 1D (NM 
178352.2) 
Precursors of the cornified envelope of 
the stratum corneum 
Eczema (Marenholz et 
al, 2011) 
ATP8B2 
ATPase, class I, type 
8B, member 2 (NM 
001005855.1) 
Operate at the plasma membrane and 
essential for endoplasmic reticulum exit 
Unknown (Harris,Arias, 
2003) 




domain 15 (NM 
001261464.1) 
Role in cell-cell interaction, cell 
migration, signal transduction, wound 
healing and pathological 
neovascularization. 
Osteoarthritis, cancer, 









(Kuwano et al, 2011) 
CDC42, cell division control protein 42  
HPV16, human papillomavirus 16 
MHC, major histocompatibility complex 
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Table 4. The correlation between the clinical parameters and the candidate genes 
determined by the discriminant analysis. 






















35.3 % 47.1 % 23.5 % 41.2 % 64.7 % 
Tissue heterogeneity 
(grade of differentiation)















35.3 % 47.1 % 47.1 % 58.8 % 76.5 % 
Stage 















52.9 % 47.1 % 70.6 % 35.3 % 58.8 % 
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Table 5. The diagnostic validity of the candidate genes for OSCC determined by ROC 
curves and logistic regression analysis. 
ADAM15 CDC7 IL12RB2 TNFRSF8
ROC curve 
Sensitivity 52.9 % 52.9 % 35.3 % 35.3 % 
Specificity 82.4 % 82.4 % 94.1 % 88.2 % 
Youden index 0.3529 0.3529 0.2941 0.2353 
AUCa (95% CIb) 
0.699 (0.518 - 
0.844) 
0.645 (0.463 - 
0.801) 




PPVc 75.0 % 75.0 % 85.7 % 75.0 % 
NPVd 63.6 % 63.6 % 59.3 % 57.7 % 
z 2.189 1.483 0.573 1.014 
p 0.0286* 0.1380 0.5663 0.3104 
Logistic regression analysis 
ORe 7.271 26.794 0.001 0.000 
p 0.029* 0.046* 0.980 0.058 
a AUC : area under the curve calculated 
b CI : confidence interval 
c PPV : positive predictive value 
d NPV : negative predictive value 
e OR : odds ratio 
* p < 0.05
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Figures and Legends 
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Figure 1. Hierarchical clustering of microarray gene expression data. The dendogram at 
the bottom lists all samples arrayed and measures their degree of relatedness in terms 
of gene expression. All samples were coded with numbers, as shown in Table 1. The 
colored bar beneath the sample identifiers marks samples from patients, where the 
Normal Group of patients with oral squamous cell carcinoma are in red and those from 
the Tumor Group are in blue (A). Genes identified by all four statistical tests (the 
permutation, LPE and t-tests and SAM) were selected as candidate genetic markers. 
The 15 genes passed Student’s t-test and SAM analysis (B). 
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Figure 2. Differential expression of 15 genes selected by microarray in oral squamous 
cell carcinoma and normal tissue. Five genes were downregulated, while the other 10 
were upregulated. The full line corresponds to the median value for each group. 
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Figure 3. qRT-PCR validation of microarray gene expression data from tested 
individuals from the Tumor Group. The quantitative reverse transcription polymerase 
chain reaction tests were performed with primer sets specific to ADAM15, CDC7, 
IL12RB2 and TNFRSF8 in 25 patients with oral squamous cell carcinoma and 20 
normal matching samples. p-values (Student’s t-test) are presented. (*P < 0.05; **P < 
0.01; ***P < 0.001) 
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Figure 4. Bar chart representation of the mRNA expression of selected genes in tumor 
and normal patient-matched specimens (tumor–normal-paired). Normalised expression 
was determined by 2-ΔΔCt, by comparing threshold cycle values of ADAM15 with β-
actin. Overexpression of all genes in tumor tissues is clearly demonstrated. Number of 
cases analysed and corresponding p-values (Student’s t-test) are provided. (*P < 0.05; 
**P < 0.01; ***P < 0.001) 
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Figure 5. Receiver operating characteristic (ROC) curve for comparing diagnostic 
validity of the candidate genes. The area under the curve (AUC) of ADAM15, CDC7, 
IL12RB2 and TNFRSF8 were 0.699, 0.645, 0.561 and 0.602, respectively. Among them, 
only ADAM5 showed statistical significance (p < 0.05). 
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국문초록
구강편평상피세포암종의 조기 진단을 위한  
후보 생체지표의 규명  
김 용 덕
서울대학교대학원 치의학과 구강악안면외과학 전공
(지도교수 이 종 호)
연구목적
구강편평상피세포암종 (oral squamous cell carcinoma : OSCC)은 빠른 성장 
속도와 침습성, 빈번한 림프절의 전이 등 그 예후가 나쁜 편이다. 따라서 
OSCC의 조기진단은 매우 중요하며, 이를 위해 임상적으로 적용가능한 생체
지표의 확립이 필요하다. 본 연구는 transcriptional signature profiling 을 분
석하여 유전학적인 연구와 생물정보학을 이용하여 OSCC의 조기진단에 사용
할 수 있는 새로운 생체지표 후보군을 제시하고자 시행하였다.  
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연구 방법
서울대학교 치과병원 구강악안면외과에서 수술 받은 OSCC 환자의 병소와 
정상조직을 습득하여 mRNA를 분리하고 cDNA를 합성하 다. 동일 환자의  
두 조직에서 유전자발현을  마이크로어레이 분석법으로 상호 비교, 분석하
다. 발현된 유전자 (differentially expressed genes: DEG)는 permutation, 
local pooled error(LPE), Student’s t-tests, significance analysis of 
microarrays (SAM)을 이용하여 생체지표 후보군으로 선별되었다. 후보군 검
증을 위해 통계적으로 유사한 분포를 갖는 validation group의 병소 및 정상
조직의 유전자로 정량적역전사중합효소연쇄반응 (qRT-PCR) 분석법으로 적
합성을 확인하 다. 임상적 변수와 유전자발현을 비교하 으며, Youden 
index를 이용하여 후보군 단독 혹은 복합적인 진단적인 가치를 비교, 분석하
다.  
결과
33,297개의 유전자 중에서 15개의 유전자가 Student’s t-test (p<0.05)와 
SAM을 통해 유의하게 발현됨이 확인되었다. 이들 중 정상조직군에 비해 10
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개의 유전자가 과발현되었고 5개의 유전자가 발현이 감소하여, OSCC에서 특
징적으로 발현됨을 확인할 수 있었다. 각 유전자의 기능과 존재론적 분석을 
기초로 4종 유전자, 즉 ADAM15, CDC7, IL12RB2, TNFRSF8를 후보군으로 
제시하였으며, qRT-PCR로 검증하였다. 특히 ADAM15과 CDC7은 모든 환
자들에게서 통계적으로 유의성있게 과발현되었다. 임상적 변수와 유전자발현
에 관한 상관관계는 후보 유전자 각자보다 복합적인 조합에서 좀더 정확도
가 높았으며, 진단적 가치는 ADAM15과 CDC7에서 유의성있게 나타났다.   
결론
본 연구 결과는 ADAM15, CDC7, IL12RB2, TNFRSF8 4종의 유전자가 
OSCC의 조기진단을 위한 생체지표 후보군으로서 가능성이 있음을 시사하였
고, 향후 OSCC의 생체지표를 연구하는데 중요한 기시점이 될것으로 본다.   
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